Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement PathwaysSeeking Alpha · Oct 14, 2026
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research · Oct 12, 2026
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire · Oct 12, 2026
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic LeukemiaGlobeNewsWire · Oct 7, 2026
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead SciencesGlobeNewsWire · Oct 5, 2026
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with PfizerGlobeNewsWire · Sep 29, 2026Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Oct 12, 2026 | -$0.60 | $4.73 | Beat |
| Jul 9, 2026 | -$0.72 | -$0.81 | Miss |
| Apr 8, 2026 | -$0.76 | -$0.79 | Miss |
| Jan 28, 2026 | -$0.84 | -$0.82 | Beat |
| Oct 9, 2025 | -$0.84 | -$1.03 | Miss |
| Jul 9, 2025 | -$0.71 | -$0.52 | Beat |